Louria Hayon Igal 4
4 · Raphael Pharmaceutical Inc. · Filed Mar 25, 2024
Insider Transaction Report
Form 4
Louria Hayon Igal
DirectorChief Technology Officer
Transactions
- Exercise of In-Money
Warrants to purchase Common Stock
2023-08-29−999,000→ 0 totalExercise: $0.01From: 2022-12-05Exp: 2024-07-05→ Common Stock (999,000 underlying) - Exercise of In-Money
Common Stock
2023-08-29$0.01/sh+999,000$9,990→ 999,000 total
Footnotes (1)
- [F1]The transaction reported is an exercise of warrants to purchase common stock. In accordance with General Instruction 4(c)(iii), the exercise price is reported under column 2 of this table.